13 July 2026NewsIn-house counselMarisa Woutersen

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

The company’s VP of IP explains how he is protecting the process, staying ahead of outside counsel, and why a biosimilar path is only a matter of time.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

In-house counsel

Exclusive: Winston Taylor’s UK head of IP on pitching $1.75bn firm’s ‘humble, but lethal’ practice

4 August 2026 A transatlantic firm with intellectual property at its heart—what’s not to like? The firm’s 30-year veteran tells WIPR why leading a recruitment drive is a “big responsibility” as the combined firm looks to out-scale the opposition.

In-house counsel

‘Engagement and collaboration’: New IP Federation president builds on strong foundations

24 July 2026 As Philips' Kevin Scott becomes the IP Federation’s new president, Sarah Speight discovers the key issues facing the membership body for in-house counsel.

More features

Novo’s Dutch win sends ‘clear message’ to unapproved semaglutide sellers

Brown Rudnick lands largest lateral IP team hire in firm history

Fran Salisbury: ‘There’s nothing quite like finding the missing piece’

K&L Gates expands European practice with Munich team hire

Patent litigator joins Baker Botts in London as UPC grows in significance

Exclusive: Winston Taylor’s UK head of IP on pitching $1.75bn firm’s ‘humble, but lethal’ practice

Insulet asks Fed Circ to rehear $59.4m trade secret reversal

Arnold & Porter adds firepower to ITC practice with new partner hire

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

More on this story

Editor's picks

Editor's picks

More features